Belgium· BE-AMP-SAM665658-00
Byooviz 10 mg/ml
A ranibizumab product containing ranibizumab, registered in Belgium by Samsung Bioepis NL. The same ATC class is registered in 15 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Ranibizumab is registered in 15 of 19 countries.
Countries holding a registration under ATC S01LA04 (ranibizumab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 9 of them publish a price we can compare per daily dose
Ranibizumab · ATC S01LA04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Ranibizumab
- Manufacturer
- Samsung Bioepis NL
- Country
- Belgium (BE)
- ATC code
- S01LA04
- ATC class
- Ranibizumab
- Defined daily dose
- 0.036 DE, IVT
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 1
- be_apb5823026
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ranibizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBYOOVIZSamsung Bioepis NL B.V., Delft
- SwedenByooviz 10 mg/ml Injektionsvätska, lösningSamsung Bioepis NL B.V.
- SpainBYOOVIZ 10 MG/ML SOLUCION INYECTABLESamsung Bioepis Nl B.V.
- PolandByoovizSamsung Bioepis NL B.V.
- NetherlandsByooviz 10 mg/ml, oplossing voor injectieSamsung Bioepis NL B.V.
- IcelandByoovizSamsung Bioepis NL B.V.
- SwitzerlandByooviz
- IrelandByooviz 10 mg/ml solution for injectionSamsung Bioepis NL B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Ximluci
- Iceland · Epruvy, Lucentis
- Liechtenstein · Epruvy, Lucentis
- Norway · Epruvy, Lucentis
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9a7df2e7-83f9-4181-94d0-d25a4fcecf4c GET /v1/drugs/9a7df2e7-83f9-4181-94d0-d25a4fcecf4c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Byooviz 10 mg/ml",
"name_fr": "Byooviz 10 mg/ml",
"name_nl": "Byooviz 10 mg/ml",
"amp_code": "SAM665658-00",
"strengths": [
"10.0000",
"10.0000",
"0.0165"
],
"pack_count": 1,
"substances": [
"Ranibizumab",
"Polysorbate 20"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Ranibizumab",
"authorisation_numbers": [
"EU/1/21/1572/003"
]
}See everything about ranibizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.